Increased systemic oxidatively generated DNA and RNA damage in schizophrenia

Psychiatry Research

Volumn 209, Issue 3, 2013, Pages 417-423

  Jorgensen, Anders ^a,b   Broedbaek, Kasper ^c,d   Fink Jensen, Anders ^a,b,e   Knorr, Ulla ^a   Greisen Soendergaard, Mia ^a   Henriksen, Trine ^c   Weimann, Allan ^c,d   Jepsen, Peter ^a   Lykkesfeldt, Jens ^e   Enghusen Poulsen, Henrik ^c,d,e   Balslev Jorgensen, Martin ^a,b,e  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

8 oxodG; 8 oxoGuo; Cortisol; Oxidative stress; Perceived stress; Schizophrenia

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 OXO 7,8 DIHYDROGUANOSINE; GUANOSINE DERIVATIVE; HYDROCORTISONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DAMAGE; FEMALE; GENETIC DAMAGE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; OXIDATION KINETICS; OXIDATIVE STRESS; PRIORITY JOURNAL; RNA DAMAGE; SCHIZOPHRENIA; SMOKING; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION;

8-OXODG; 8-OXOGUO; CORTISOL; OXIDATIVE STRESS; PERCEIVED STRESS; SCHIZOPHRENIA;

ADULT; CASE-CONTROL STUDIES; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; GUANOSINE; HUMANS; HYDROCORTISONE; MALE; MALONDIALDEHYDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RETROSPECTIVE STUDIES; RNA; SALIVA; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84885474230     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.01.033     Document Type: Article

References (57)

1. Andreoli R., Mutti A., Goldoni M., Manini P., Apostoli P., De Palma G. Reference ranges of urinary biomarkers of oxidized guanine in (2'-deoxy)ribonucleotides and nucleic acids. Free Radical Biology and Medicine 2011, 50:254-261.
2. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003, 62:195-204.
3. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., Bennett C., Ranjekar P.K., Mahadik S.P. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003, 53:56-64.
4. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Judd F., Katz F., Katz P., Ording-Jespersen S., Little J., Conus P., Cuenod M., Do K.Q., Bush A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biological Psychiatry 2008, 64:361-368.
5. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nature Medicine 2004, 10(Suppl.):S2-S9.
6. Broedbaek K., Siersma V., Henriksen T., Weimann A., Petersen M., Andersen J.T., Jimenez-Solem E., Stovgaard E.S., Hansen L.J., Henriksen J.E., Bonnema S.J., de Fine Olivarius N., Poulsen H.E. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care 2011, 34:2594-2596.
7. Cabungcal J.H., Steullet P., Kraftsik R., Cuenod M., Do K.Q. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biological Psychiatry 2012, (Epub ahead of print).
8. Caro P., Gomez J., Sanz A., Portero-Otin M., Pamplona R., Barja G. Effect of graded corticosterone treatment on aging-related markers of oxidative stress in rat liver mitochondria. Biogerontology 2007, 8:1-11.
9. Catts V.S., Catts S.V., Jablensky A., Chandler D., Weickert C.S., Lavin M.F. Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia. World Journal of Biological Psychiatry 2012, 13:114-125.
10. Che Y., Wang J.F., Shao L., Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. Journal of Psychiatry and Neuroscience 2010, 35:296-302.
11. Chengappa K.N., Turkin S.R., Desanti S., Bowie C.R., Brar J.S., Schlicht P.J., Murphy S.L., Hetrick M.L., Bilder R., Fleet D. A preliminary, randomized, double-blind, placebo-controlled trial of l-carnosine to improve cognition in schizophrenia. Schizophrenia Research 2012, 142:145-152.
12. Choy K.H., Dean O., Berk M., Bush A.I., van den Buuse M. Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. European Journal of Pharmacology 2010, 649:224-228.
13. Cohen S., Williamson G. Perceived stress in a probability sample if the United States. The Social Psychology of Health: Claremont Symposium on Applied Social Psychology 1988, Sage, Newbury Park, CA. S. Spacapan, S. Oskamp (Eds.).
14. Dakhale G.N., Khanzode S.D., Khanzode S.S., Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berlin) 2005, 182:494-498.
15. Deng X.S., Tuo J., Poulsen H.E., Loft S. Prevention of oxidative DNA damage in rats by brussels sprouts. Free Radical Research 1998, 28:323-333.
16. Du J., Wang Y., Hunter R., Wei Y., Blumenthal R., Falke C., Khairova R., Zhou R., Yuan P., Machado-Vieira R., McEwen B.S., Manji H.K. Dynamic regulation of mitochondrial function by glucocorticoids. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3543-3548.
17. Epel E.S., Blackburn E.H., Lin J., Dhabhar F.S., Adler N.E., Morrow J.D., Cawthon R.M. Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:17312-17315.
18. Evans M.D., Olinski R., Loft S., Cooke M.S. Toward consensus in the analysis of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a noninvasive biomarker of oxidative stress. FASEB Journal 2010, 24:1249-1260.
19. Evans M.D., Saparbaev M., Cooke M.S. DNA repair and the origins of urinary oxidized 2'-deoxyribonucleosides. Mutagenesis 2010, 25:433-442.
20. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
21. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., Tosic M., Werge T., Cuenod M., Do K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16621-16626.
22. Harrison D., Griendling K.K., Landmesser U., Hornig B., Drexler H. Role of oxidative stress in atherosclerosis. American Journal of Cardiology 2003, 91:7A-11A.
23. Henriksen T., Hillestrom P.R., Poulsen H.E., Weimann A. Automated method for the direct analysis of 8-oxo-guanosine and 8-oxo-2'-deoxyguanosine in human urine using ultraperformance liquid chromatography and tandem mass spectrometry. Free Radical Biology and Medicine 2009, 47:629-635.
24. Hoang U., Stewart R., Goldacre M.J. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. British Medical Journal 2011, 343:d5422.
25. Jablensky A., Angelicheva D., Donohoe G.J., Cruickshank M., Azmanov D.N., Morris D.W., McRae A., Weickert C.S., Carter K.W., Chandler D., Alexandrov B., Usheva A., Morar B., Verbrugghe P.L., Filipovska A., Rackham O., Bishop A.R., Rasmussen K.O., Dragovic M., Cooper M., Phillips M., Badcock J., Bramon-Bosch E., Almeida O.P., Flicker L., Gill M., Corvin A., Macgregor S., Kalaydjieva L. Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia. Molecular Psychiatry 2012, 17:1328-1339.
26. Jeste D.V., Wolkowitz O.M., Palmer B.W. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophrenia Bulletin 2011, 37:451-455.
27. Joergensen A., Broedbaek K., Weimann A., Semba R.D., Ferrucci L., Joergensen M.B., Poulsen H.E. Association between urinary excretion of cortisol and markers of oxidatively damaged DNA and RNA in humans. PloS One 2011, 6:e20795.
28. Kao H.T., Cawthon R.M., Delisi L.E., Bertisch H.C., Ji F., Gordon D., Li P., Benedict M.M., Greenberg W.M., Porton B. Rapid telomere erosion in schizophrenia. Molecular Psychiatry 2008, 13:118-119.
29. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
30. Kirkpatrick B., Messias E., Harvey P.D., Fernandez-Egea E., Bowie C.R. Is schizophrenia a syndrome of accelerated aging?. Schizophrenia Bulletin 2008, 34:1024-1032.
31. Kirschbaum C., Hellhammer D.H. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994, 19:313-333.
32. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Ruther E., Emrich H.M., Schneider U., Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. Journal of Neuropsychiatry and Clinical Neurosciences 2005, 17:227-231.
33. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Cereser K.M., Gomes F.A., Belmonte-de-Abreu P.S., Berk M., Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Progress in Neuro-psychopharmacology and Biological Psychiatry 2008, 32:1677-1681.
34. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D., Fornari E., Meuli R., Solida A., Vianin P., Cuenod M., Buclin T., Do K.Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2007, 33:2187-2199.
35. Loft S., Larsen P.N., Rasmussen A., Fischer-Nielsen A., Bondesen S., Kirkegaard P., Rasmussen L.S., Ejlersen E., Tornoe K., Bergholdt R. Oxidative DNA damage after transplantation of the liver and small intestine in pigs. Transplantation 1995, 59:16-20.
36. Lykkesfeldt J. Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clinical Chemistry 2001, 47:1725-1727.
37. Lykkesfeldt J. Ascorbate and dehydroascorbic acid as reliable biomarkers of oxidative stress: analytical reproducibility and long-term stability of plasma samples subjected to acidic deproteinization. Cancer Epidemiology, Biomarkers and Prevention 2007, 16:2513-2516.
38. Lykkesfeldt J. Malondialdehyde as biomarker of oxidative damage to lipids caused by smoking. Clinica Chimica Acta Journal 2007, 380:50-58.
39. Mansour H., Chowdari K., Fathi W., Elassy M., Ibrahim I., Wood J., Bamne M., Tobar S., Yassin A., Salah H., Elsayed H., Eissa A., El-Boraie H., Ibrahim N.E., Elsayed M., El-Bahaei W., Gomaa Z., El-Chennawi F., Nimgaonkar V.L. Does telomere length mediate associations between inbreeding and increased risk for bipolar I disorder and schizophrenia?. Psychiatry Research 2011, 188:129-132.
40. Miller G.E., Chen E., Sze J., Marin T., Arevalo J.M., Doll R., Ma R., Cole S.W. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biological Psychiatry 2008, 64:266-272.
41. Moller P., Lohr M., Folkmann J.K., Mikkelsen L., Loft S. Aging and oxidatively damaged nuclear DNA in animal organs. Free Radical Biology and Medicine 2010, 48:1275-1285.
42. Nishioka N., Arnold S.E. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. American Journal of Geriatric Psychiatry 2004, 12:167-175.
43. Nunomura A., Hofer T., Moreira P.I., Castellani R.J., Smith M.A., Perry G. RNA oxidation in Alzheimer disease and related neurodegenerative disorders. Acta Neuropathologica 2009, 118:151-166.
44. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S., Karp N.A., Hester S., Tkachev D., Mimmack M.L., Yolken R.H., Webster M.J., Torrey E.F., Bahn S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 2004, 9(684-697):643.
45. Pruessner J.C., Kirschbaum C., Meinlschmid G., Hellhammer D.H. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 2003, 28:916-931.
46. Psimadas D., Messini-Nikolaki N., Zafiropoulou M., Fortos A., Tsilimigaki S., Piperakis S.M. DNA damage and repair efficiency in lymphocytes from schizophrenic patients. Cancer Letters 2004, 204:33-40.
47. Regenold W.T., Phatak P., Marano C.M., Sassan A., Conley R.R., Kling M.A. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biological Psychiatry 2009, 65:489-494.
48. Rosenfeld M., Brenner-Lavie H., Ari S.G., Kavushansky A., Ben-Shachar D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biological Psychiatry 2011, 69:980-988.
49. Sahin E., DePinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
50. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 2001, 49:1-52.
51. Tosic M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., Matthey M.L., Parnas J., Preisig M., Saraga M., Solida A., Timm S., Wang A.G., Werge T., Cuenod M., Do K.Q. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. American Journal of Human Genetics 2006, 79:586-592.
52. Turrens J.F. Mitochondrial formation of reactive oxygen species. Journal of Physiology 2003, 552:335-344.
53. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry 2006, 63:139-149.
54. Wahlbeck K., Westman J., Nordentoft M., Gissler M., Laursen T.M. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. British Journal of Psychiatry 2011, 199:453-458.
55. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., Sartorius N. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 1990, 47:589-593.
56. Young J., McKinney S.B., Ross B.M., Wahle K.W., Boyle S.P. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostglandines, Leukotrienes and Essential Fatty Acids 2007, 76:73-85.
57. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81:291-300.